CREBBP and precursor B-cell acute lymphoblastic leukemia: EP300- and CREBBP-ZNF384 rearranged B-ALL result in loss of histone lysine acetyltransferase activity, reduction of histone acetylation and increased sensitivity to HDACi, opening the possibility to use these inhibitors for these specific B-ALL subtypes.